Cargando…

Review of Levetiracetam as a First Line Treatment in Status Epilepticus in the Adult Patients – What Do We Know so Far?

With the advent of new antiepileptic drugs comes the potential for significant advances in the emergent management of status epilepticus. Traditional antiepileptic drugs possess side effect profiles that may limit their clinical utility or lead to increased patient morbidity or mortality. The relati...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Hae Won, Davis, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3733027/
https://www.ncbi.nlm.nih.gov/pubmed/23935593
http://dx.doi.org/10.3389/fneur.2013.00111
_version_ 1782279320699404288
author Shin, Hae Won
Davis, Robin
author_facet Shin, Hae Won
Davis, Robin
author_sort Shin, Hae Won
collection PubMed
description With the advent of new antiepileptic drugs comes the potential for significant advances in the emergent management of status epilepticus. Traditional antiepileptic drugs possess side effect profiles that may limit their clinical utility or lead to increased patient morbidity or mortality. The relatively recent development of levetiracetam shows promise for effective control of acute status epilepticus in adults, but current objective data of its use as a first-line agent for control of status is quite limited. This paper serves to examine existing literature while considering levetiracetam as a first-line therapy in status in the adult patient population. Although existing studies are narrow in their scope, the present data lay a substantial foundation for further investigation of levetiracetam as a primary therapy in acute status epilepticus.
format Online
Article
Text
id pubmed-3733027
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-37330272013-08-09 Review of Levetiracetam as a First Line Treatment in Status Epilepticus in the Adult Patients – What Do We Know so Far? Shin, Hae Won Davis, Robin Front Neurol Neuroscience With the advent of new antiepileptic drugs comes the potential for significant advances in the emergent management of status epilepticus. Traditional antiepileptic drugs possess side effect profiles that may limit their clinical utility or lead to increased patient morbidity or mortality. The relatively recent development of levetiracetam shows promise for effective control of acute status epilepticus in adults, but current objective data of its use as a first-line agent for control of status is quite limited. This paper serves to examine existing literature while considering levetiracetam as a first-line therapy in status in the adult patient population. Although existing studies are narrow in their scope, the present data lay a substantial foundation for further investigation of levetiracetam as a primary therapy in acute status epilepticus. Frontiers Media S.A. 2013-08-05 /pmc/articles/PMC3733027/ /pubmed/23935593 http://dx.doi.org/10.3389/fneur.2013.00111 Text en Copyright © 2013 Shin and Davis. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Shin, Hae Won
Davis, Robin
Review of Levetiracetam as a First Line Treatment in Status Epilepticus in the Adult Patients – What Do We Know so Far?
title Review of Levetiracetam as a First Line Treatment in Status Epilepticus in the Adult Patients – What Do We Know so Far?
title_full Review of Levetiracetam as a First Line Treatment in Status Epilepticus in the Adult Patients – What Do We Know so Far?
title_fullStr Review of Levetiracetam as a First Line Treatment in Status Epilepticus in the Adult Patients – What Do We Know so Far?
title_full_unstemmed Review of Levetiracetam as a First Line Treatment in Status Epilepticus in the Adult Patients – What Do We Know so Far?
title_short Review of Levetiracetam as a First Line Treatment in Status Epilepticus in the Adult Patients – What Do We Know so Far?
title_sort review of levetiracetam as a first line treatment in status epilepticus in the adult patients – what do we know so far?
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3733027/
https://www.ncbi.nlm.nih.gov/pubmed/23935593
http://dx.doi.org/10.3389/fneur.2013.00111
work_keys_str_mv AT shinhaewon reviewoflevetiracetamasafirstlinetreatmentinstatusepilepticusintheadultpatientswhatdoweknowsofar
AT davisrobin reviewoflevetiracetamasafirstlinetreatmentinstatusepilepticusintheadultpatientswhatdoweknowsofar